Eukaryotic Transcription Activation: Right on Target

Howard Hughes Medical Institute, Program in Gene Function and Expression, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Molecular Cell (Impact Factor: 14.46). 06/2005; 18(4):399-402. DOI: 10.1016/j.molcel.2005.04.017
Source: PubMed

ABSTRACT The unambiguous identification of the direct targets of eukaryotic transcriptional activators has been a major challenge in the field. Recently, the authentic targets of several yeast and mammalian activators have been determined, and the results of these studies have important implications for our understanding of transcriptional activation mechanisms.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chromatin structure imposes significant obstacles on all aspects of transcription that are mediated by RNA polymerase II. The dynamics of chromatin structure are tightly regulated through multiple mechanisms including histone modification, chromatin remodeling, histone variant incorporation, and histone eviction. In this Review, we highlight advances in our understanding of chromatin regulation and discuss how such regulation affects the binding of transcription factors as well as the initiation and elongation steps of transcription.
    Cell 03/2007; 128(4):707-19. DOI:10.1016/j.cell.2007.01.015 · 33.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Not available Cellular and Molecular Biology, Institute for
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Eukaryotic transcription activators normally consist of a sequence-specific DNA-binding domain (DBD) and a transcription activation domain (AD). While many sequence patterns and motifs have been defined for DBDs, ADs do not share easily recognizable motifs or structures. We report herein that the N-terminal domain of yeast valyl-tRNA synthetase can function as an AD when fused to a DNA-binding protein, LexA, and turn on reporter genes with distinct LexA-responsive promoters. The transcriptional activity was mainly attributed to a five-residue peptide, WYDWW, near the C-terminus of the N domain. Remarkably, the pentapeptide per se retained much of the transcriptional activity. Mutations which substituted tryptophan residues for both of the non-tryptophan residues in the pentapeptide (resulting in W5) significantly enhanced its activity (~1.8-fold), while mutations which substituted aromatic residues with alanine residues severely impaired its activity. Accordingly, a much more active peptide, pentatryptophan (W7), was produced, which elicited ~3-fold higher activity than that of the native pentapeptide and the N domain. Further study indicated that W7 mediates transcription activation through interacting with the general transcription factor, TFIIB. Since W7 shares no sequence homology or features with any known transcription activators, it may represent a novel class of AD.
    BMC Molecular Biology 11/2010; 11:85. DOI:10.1186/1471-2199-11-85 · 2.06 Impact Factor